Elisabeth Bjork
Director at Pharvaris N.V. (PHVS); Director at Rocket Pharmaceuticals, Inc. (RCKT)
Purchase track record
Not enough history. Based on 1 purchase with a full 90 days of price history.
—
Avg. 90-day return-2.3%
vs. S&P 500+2.2%
Beat the market100%
Paper profit on buys−$9K
Total bought / sold$34K / $2.3M
Reported trades
| Filed | Stock | Type | Shares | Price | Value | Since |
|---|---|---|---|---|---|---|
| Sep 21SEC | PHVSPharvaris N.V. | Sell | 52,50015,167 held (−78%) | $37.89 | $2.0M | -17.9% |
| May 22SEC | PHVSPharvaris N.V. | Sell Plan | 10,00015,167 held (−40%) | $29.32 | $293K | +6.1% |
| Jan 6SEC | RCKTRocket Pharmaceuticals, Inc. | Buy | 10,00050,000 held (+25%) | $3.44 | $34K | -25.6% |
- Sell
Director Elisabeth Bjork sold $2.0M of PHVS at $37.89 — cuts the stake by 78%.
- Sell
Director Elisabeth Bjork sold $293K of PHVS at $29.32 — cuts the stake by 40%; pre-scheduled 10b5-1 plan sale.
- Buy
Director Elisabeth Bjork bought $34K of RCKT at $3.44 — first open-market purchase in our records; raises the stake by 25%.